FACTBOX- The race for a coronavirus vaccine

 (Updates Pfizer, Novavax, Bharat Biotech, Clover, CureVac, CanSino Biologics)
    Nov 9 (Reuters) - Pfizer and German partner BioNTech on Monday became the first
drugmakers to show successful data from a large-scale clinical trial of a coronavirus vaccine, priming it
for possible speedy regulatory approvals.
    Moderna and AstraZeneca, are the other frontrunners in the race to successfully develop a safe and
effective COVID-19 vaccine. There are 47 vaccine candidates in human trials worldwide.  
    The following table tracks the latest developments from major drugmakers and research institutes that
have moved beyond testing their vaccine candidates in early-stage trials:
    For a separate FACTBOX on vaccines in final stages of development, click, and for a
FACTBOX on treatments under development, click
 Company                      State of play                   Development phase 
 AstraZeneca                  U.S. trial resumed after a      Late-stage trials             
                              probe into a patient's          
                              illness; vaccine produces       
                              immune response in both young   
                              and old adults                  
 Sinopharm                    Prelim data from late-stage     Late-stage trials underway in China, Brazil
                              trial in Brazil showed vaccine  and Bahrain; UAE grants emergency approval
                              candidate is safe                            
 Pfizer         and BioNTech  The companies said vaccine was  Pfizer expects to seek broad U.S. emergency
 SE                           more than 90% effective and     use authorization of vaccine for people aged
                              they have so far found no       16 to 85 in coming weeks             
                              serious safety concerns         
 Moderna Inc                  Completed enrollment of 30,000  30,000-subject final stage trial began on
                              subjects in a late-stage        July 27             
                              trial. Interim results from     
                              the trial expected in November  
 Sinovac Biotech              CoronaVac approved for          Late stage trials in Brazil, Indonesia and
                              emergency use in China to       Turkey underway; Prelim data expected in
                              vaccinate high-risk groups      November             
 CanSino Biologics            Early results showed vaccine    Vaccine candidate in final-stage trials, has
                              is safe                         been approved for use by the Chinese
                                                              military. Late-stage trial underway in
                                                              Pakistan and Mexico             
 Inovio Pharma                U.S. health regulator pauses    Company aims to respond to FDA's queries in
                              company's plans to start final  October             
                              trials as agency seeks more     
 Moscow's Gamaleya Research   Russia has temporarily stopped  Vaccine, approved in Russia, produced
 Institute                    vaccinating new volunteers in   antibody response in all participants in
                              its COVID-19 vaccine trial      early-stage trials             
 Vector Institute in Siberia  A second Russian vaccine,       Early-stage trial             
                              developed was granted           
                              regulatory approval in the      
                              country on Oct. 14.             
 Chongqing Zhifei Biological  Unit Anhui Zhifei Longcom       Mid-stage trial             
 Products                     Biopharmaceutical has begun     
                              human trials                    
 Bharat Biotech               Vaccine candidate found to be   Plans to enroll about 25,000 to 26,000
                              safe in early-to-mid stage      participants in around 12-14 states for
                              trials; Plans to launch its     late-stage trials             
                              COVID-19 vaccine candidate in   
                              Q2, 2021                        
 Johnson & Johnson            Large U.S. vaccine trial set    Results from the trial expected by the end of
                              to resume after it was paused   2020 or early 2021             
                              due to illness in a study       
                              volunteer. Brazil authorizes    
                              resumption of clinical trial    
 Novavax                      On track to start late-stage    Late-stage study underway in UK             
                              trial in U.S. in November,      
                              vaccine candidate gets FDA      
                              'fast track' status             
 GlaxoSmithKline              First data on the vaccine it    Early-to-mid stage trial            
                              is developing with Sanofi       
                                        is expected by the    
                              end of the year                 
 CureVac                      Vaccine produces immune         Plans to launch final stage of testing
                              response in humans              involving about 30,000 participants before
                                                              year end             
 Clover Biopharmaceuticals    Chinese developer to receive    Early-stage trials; Plans to conduct
                              up to $328 mln from an          late-stage clinical trials in Philippines
                              epidemic response group                     
 Genexine                     South Korean company has begun  Early-stage trials             
                              human trials                    
 Not applicable               Institute of Medical Biology    Mid-stage trials             
                              at Chinese Academy of Medical   
                              Sciences testing a vaccine      
 Walvax Biotechnology         Trials sponsored by Walvax and  Mexico to conduct late-stage trials
                              a Chinese military research                 
                              institute, have begun           
  The following table lists vaccines whose development timeline slightly lags the rest:
 Medicago                     Early-stage trials             
 Cadila Healthcare            Early-stage trials             
 Not applicable               Early-stage testing (
 Arcturus Therapeutics        Early-stage testing             
          and Duke-NUS        
 Osaka University, AnGes,     Early-stage testing (
 Takara Bio                   
 Kentucky Bioprocessing       Early-stage testing planned (
 Vaxine Pty/Medytox           Early-stage testing             
 Medigen Vaccine Biologics    Early-stage trial (
 Merck & Co                   Early-stage trial planned             
 ReiThera/Leukocare/Univerce  Early-stage trial (
 Cuba's Instituto Finlay de   Early-stage trial (
 Merck's unit/Institute       Early-stage trial (
 Pasteur/University of        
 Pittsburg CVR                
 Research Institute for       Early-mid stage trials (
 Biological Safety            
 Problems, Rep of Kazakhstan  
 West China Hospital,         Early-stage trials (
 Sichuan University           
 Beijing Wantai Biological    Early-stage trials (
 Pharmacy/Xiamen University   
 COVAXX                       Early-stage trials in Taiwan             
 University Hospital          Early-stage studies (
 Institute of Biotechnology,  Early-stage studies (
 Academy of                   
 Military Medical Sciences,   
 PLA of China                 
 Germany's IDT Biologika      Early-stage trial             
 Vaxart Inc                   Early-stage trial             
 Imperial College London      Early-stage trials             
 SpyBiotech/ Serum Institute  Early-stage trials             
 of India                     

 (Reporting by Vishwadha Chander and Manas Mishra in Bengaluru; Editing by Maju Samuel and Shounak